These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

304 related articles for article (PubMed ID: 17218847)

  • 1. Update on ovarian cancer screening.
    Munkarah A; Chatterjee M; Tainsky MA
    Curr Opin Obstet Gynecol; 2007 Feb; 19(1):22-6. PubMed ID: 17218847
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Diagnostic Value of Transvaginal Sonograph (TVS), Color Doppler, and Serum Tumor Marker CA125, CEA, and AFP in Ovarian Cancer.
    Zhang F; Zhang ZL
    Cell Biochem Biophys; 2015 Jun; 72(2):353-7. PubMed ID: 25582421
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Studies on angiogenesis in the benign and malignant ovarian neoplasms with the use of color and pulsed Doppler sonography and serum CA-125, CA-19.9, CA-72.4 and vascular endothelial growth factor measurements.
    Czekierdowski A
    Ann Univ Mariae Curie Sklodowska Med; 2002; 57(1):113-31. PubMed ID: 12898913
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Status of tumor markers in ovarian cancer screening.
    Bast RC
    J Clin Oncol; 2003 May; 21(10 Suppl):200s-205s. PubMed ID: 12743135
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Program for early detection of ovarian cancer for women as prophylaxis provided at a municipal hospital].
    Cnota W; Sodowski K; Olesiak-Andryszczak M; Pilch-Kowalczyk M
    Wiad Lek; 2004; 57 Suppl 1():43-7. PubMed ID: 15884203
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Early detection of ovarian cancer: new technologies in pursuit of a disease that is neither common nor rare.
    Bast RC
    Trans Am Clin Climatol Assoc; 2004; 115():233-47; discussion 247-8. PubMed ID: 17060970
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The efficacy of transvaginal sonographic screening in asymptomatic women at risk for ovarian cancer.
    van Nagell JR; DePriest PD; Reedy MB; Gallion HH; Ueland FR; Pavlik EJ; Kryscio RJ
    Gynecol Oncol; 2000 Jun; 77(3):350-6. PubMed ID: 10831341
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Advances in the early detection of ovarian carcinoma.
    Garner EI
    J Reprod Med; 2005 Jun; 50(6):447-53. PubMed ID: 16050569
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Performance of ultrasound as a second line test to serum CA125 in ovarian cancer screening.
    Menon U; Talaat A; Rosenthal AN; Macdonald ND; Jeyerajah AR; Skates SJ; Sibley K; Oram DH; Jacobs IJ
    BJOG; 2014 Dec; 121 Suppl 7():35-9. PubMed ID: 25488086
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ovarian cancer screening.
    Kurjak A; Predanic M
    Curr Opin Obstet Gynecol; 1994 Feb; 6(1):67-74. PubMed ID: 8180353
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The early detection of ovarian cancer: from traditional methods to proteomics. Can we really do better than serum CA-125?
    Nossov V; Amneus M; Su F; Lang J; Janco JM; Reddy ST; Farias-Eisner R
    Am J Obstet Gynecol; 2008 Sep; 199(3):215-23. PubMed ID: 18468571
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Diagnostic value of the morphological ultrasound score system and the serum concentration of CA 125 in the diagnosis of malignant ovarian cancer].
    Brazert J; Pietryga M; Szabłoński W; Persona-Sliwińska A; Biczysko R
    Ginekol Pol; 2003 Dec; 74(12):1542-8. PubMed ID: 15029747
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ovarian cancer screening.
    Mackey SE; Creasman WT
    J Clin Oncol; 1995 Mar; 13(3):783-93. PubMed ID: 7884436
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Preoperative sensitivity and specificity for early-stage ovarian cancer when combining cancer antigen CA-125II, CA 15-3, CA 72-4, and macrophage colony-stimulating factor using mixtures of multivariate normal distributions.
    Skates SJ; Horick N; Yu Y; Xu FJ; Berchuck A; Havrilesky LJ; de Bruijn HW; van der Zee AG; Woolas RP; Jacobs IJ; Zhang Z; Bast RC
    J Clin Oncol; 2004 Oct; 22(20):4059-66. PubMed ID: 15381683
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Population screening and early detection of ovarian cancer in asymptomatic women.
    Nelson AE; Francis JE; Zorbas H;
    Aust N Z J Obstet Gynaecol; 2009 Oct; 49(5):448-50. PubMed ID: 19780723
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ovarian cancer screening. The use of serial complementary tumor markers to improve sensitivity and specificity for early detection.
    Berek JS; Bast RC
    Cancer; 1995 Nov; 76(10 Suppl):2092-6. PubMed ID: 8635006
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Screening for ovarian cancer in the general population.
    Chu CS; Rubin SC
    Best Pract Res Clin Obstet Gynaecol; 2006 Apr; 20(2):307-20. PubMed ID: 16364690
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CA125 and transvaginal ultrasound monitoring in high-risk women cannot prevent the diagnosis of advanced ovarian cancer.
    Olivier RI; Lubsen-Brandsma MA; Verhoef S; van Beurden M
    Gynecol Oncol; 2006 Jan; 100(1):20-6. PubMed ID: 16188302
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Three-dimensional ultrasonography and power Doppler in ovarian cancer screening of asymptomatic peri- and postmenopausal women.
    Kurjak A; Prka M; Arenas JM; Sparac V; Merce LT; Corusic A; Ivancic-Kosuta M
    Croat Med J; 2005 Oct; 46(5):757-64. PubMed ID: 16158468
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of transvaginal color Doppler sonography, transvaginal sonography and CA 125 for prediction of ovarian malignancy.
    Sengoku K; Satoh T; Saitoh S; Abe M; Ishikawa M
    Int J Gynaecol Obstet; 1994 Jul; 46(1):39-43. PubMed ID: 7805982
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.